Budesonide Maintains IgA Nephropathy Kidney Failure Reduction, Quality of Life at 2 Years
New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.
Source: hcplive.com
Nefigard Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nefigard Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nefigard Phase Today - Breaking & Trending Today
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB , today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology's...
Source: marketscreener.com
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
Source: prnewswire.com
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript
Operator: Welcome to the Calliditas Therapeutics Q4 2023 Report. For the first part of the conference call, the participants will be in listen-only mode.
Source: insidermonkey.com
Calliditas Interim Report January - September 2023
/PRNewswire/ -- The Lancet publication of full Phase 3 data set In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd,...
Source: prnewswire.com